
USA - NYSE:CFX - Common Stock
The current stock price of CFX is 39.06 null. In the past month the price increased by 7.54%. In the past year, price decreased by -10.02%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| PH | PARKER HANNIFIN CORP | 28.38 | 98.26B | ||
| ITW | ILLINOIS TOOL WORKS | 23.66 | 71.10B | ||
| SYM | SYMBOTIC INC | 515.6 | 45.67B | ||
| XYL | XYLEM INC | 31.03 | 36.56B | ||
| OTIS | OTIS WORLDWIDE CORP | 23.17 | 35.93B | ||
| IR | INGERSOLL-RAND INC | 24.7 | 31.61B | ||
| DOV | DOVER CORP | 19.29 | 24.63B | ||
| SNA | SNAP-ON INC | 17.95 | 17.80B | ||
| PNR | PENTAIR PLC | 22.29 | 17.62B | ||
| FTV | FORTIVE CORP | 15.36 | 17.05B | ||
| ITT | ITT INC | 29.75 | 14.78B | ||
| GGG | GRACO INC | 29.16 | 13.62B |
Colfax Corp. operates as a diversified technology company. The company is headquartered in Wilmington, Delaware and currently employs 16,200 full-time employees. The company went IPO on 2008-05-08. The Company’s segments include Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures and supplies consumable products and equipment, including cutting, joining, and automated welding products, as well as gas control equipment. Its fabrication technology products are marketed under several brands, including ESAB. The Medical Technology segment develops, manufactures and distributes medical devices and services across the continuum of patient care from injury prevention to joint replacement to the rehabilitation after surgery, injury from degenerative disease, enabling people to regain or maintain their natural motion. Its products are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, athletic trainers and other healthcare professionals.
COLFAX CORP
2711 Centerville Road, Suite 400
Wilmington DELAWARE 20701 US
CEO: Matthew L. Trerotola
Employees: 16200
Phone: 13022529160.0
Colfax Corp. operates as a diversified technology company. The company is headquartered in Wilmington, Delaware and currently employs 16,200 full-time employees. The company went IPO on 2008-05-08. The Company’s segments include Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures and supplies consumable products and equipment, including cutting, joining, and automated welding products, as well as gas control equipment. Its fabrication technology products are marketed under several brands, including ESAB. The Medical Technology segment develops, manufactures and distributes medical devices and services across the continuum of patient care from injury prevention to joint replacement to the rehabilitation after surgery, injury from degenerative disease, enabling people to regain or maintain their natural motion. Its products are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, athletic trainers and other healthcare professionals.
The current stock price of CFX is 39.06 null. The price decreased by -3.77% in the last trading session.
CFX does not pay a dividend.
CFX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
19 analysts have analysed CFX and the average price target is 51.43 null. This implies a price increase of 31.66% is expected in the next year compared to the current price of 39.06.
The Revenue of COLFAX CORP (CFX) is expected to grow by 7.2% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
You can find the ownership structure of COLFAX CORP (CFX) on the Ownership tab.
ChartMill assigns a technical rating of 1 / 10 to CFX. When comparing the yearly performance of all stocks, CFX is a bad performer in the overall market: 61.5% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to CFX. CFX may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months CFX reported a non-GAAP Earnings per Share(EPS) of 2.13. The EPS increased by 53.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.86% | ||
| ROA | 0.84% | ||
| ROE | 1.55% | ||
| Debt/Equity | 0.45 |
19 analysts have analysed CFX and the average price target is 51.43 null. This implies a price increase of 31.66% is expected in the next year compared to the current price of 39.06.
For the next year, analysts expect an EPS growth of 241.51% and a revenue growth 7.2% for CFX